CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
erlotinib hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00524121
NCT00524121Phase 2Completed
CompareCT.gov

Phase II Study of Erlotinib (Tarceva®) and Radiotherapy for Elderly Patients With Esophageal Carcinoma

Roswell Park Cancer Institute·interventional·Posted Sep 3, 2007·Updated Apr 14, 2016

In Brief

A Phase 2 clinical trial evaluating erlotinib hydrochloride, immunohistochemistry staining method, and 1 other intervention for Esophageal Cancer. Completed, enrolled 22 participants across 1 site.

Detailed Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with radiation therapy works in treating older patients with stage I, stage II, stage III, or stage IV esophageal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 3, 2007
Enrollment StartMar 1, 2006
Primary CompletionMay 1, 2010
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.8 years ago

Interventions

erlotinib hydrochloridedrug

Oral

immunohistochemistry staining methodother

Correlative Study

radiation therapyradiation

Radiation Treatment